EUVIMEDEUVIMED entdecken
Crossref

Invention of MK-7845, a SARS-CoV-2 3CL Protease Inhibitor Employing a Novel Difluorinated Glutamine Mimic

Valerie W Shurtleff iD, Mark E Layton iD, Craig A Parish iD, James J Perkins iD, John D Schreier, Yunyi Wang, Gregory C Adam, Nadine Alvarez, Soheila Bahmanjah, Carolyn M Bahnck-Teets, Christopher W Boyce, Christine Burlein und 36 weitere

Journal of Medicinal Chemistry · 14.03.2024 · 67 (5) · 3935-3958

DOI: 10.1021/acs.jmedchem.3c02248 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 16.02.2024. Verfasst von Valerie W Shurtleff und 47 weiteren Autor:innen. Beteiligte Einrichtung: Merck & Co., Inc., West Point, Pennsylvania 19486, United States. Hauptthemen laut MEDLINE: Glutamine, COVID-19. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases, Metropolitan AntiViral Drug Accelerator.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

As SARS-CoV-2 continues to circulate, antiviral treatments are needed to complement vaccines. The virus's main protease, 3CLPro, is an attractive drug target in part because it recognizes a unique cleavage site, which features a glutamine residue at the P1 position and is not utilized by human proteases. Herein, we report the invention of MK-7845, a novel reversible covalent 3CLPro inhibitor. While most covalent inhibitors of SARS-CoV-2 3CLPro reported to date contain an amide as a Gln mimic at P1, MK-7845 bears a difluorobutyl substituent at this position. SAR analysis and X-ray crystallographic studies indicate that this group interacts with His163, the same residue that forms a hydrogen bond with the amide substituents typically found at P1. In addition to promising in vivo efficacy and an acceptable projected human dose with unboosted pharmacokinetics, MK-7845 exhibits favorable properties for both solubility and absorption that may be attributable to the unusual difluorobutyl substituent.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlutamineCOVID-19HumansSARS-CoV-2Cysteine EndopeptidasesInventionsProtease InhibitorsAmidesAntiviral Agents

Substanzen

GlutamineCysteine EndopeptidasesProtease InhibitorsAmidesAntiviral Agents

Autor:innen und Institutionen

  • Merck & Co., Inc., West Point, Pennsylvania 19486, United States.
  • Merck & Co., Inc., Rahway, New Jersey 07065, United States.
  • Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey 07110, United States.
  • MSD (U.K.) Limited, London EC2M 6UR, U.K.
  • Viva Biotech Ltd., Shanghai 201318, China.

ORCID-Profile: Valerie W Shurtleff, Mark E Layton, Craig A Parish, James J Perkins, Wonsuk Chang, Manuel de Lera Ruiz, Christopher C Nawrat

Förderung

  • NIAID NIH HHS
  • National Institute of Allergy and Infectious Diseases
  • Metropolitan AntiViral Drug Accelerator

Zitieren

APA

Shurtleff, V. W., Layton, M. E., Parish, C. A., Perkins, J. J., Schreier, J. D., Wang, Y., Adam, G. C., Alvarez, N., Bahmanjah, S., Bahnck-Teets, C. M., Boyce, C. W., Burlein, C., Cabalu, T. D., Campbell, B. T., Carroll, S. S., Chang, W., de Lera Ruiz, M., Dolgov, E., Fay, J. F., …, & McCauley, J. A. (2024). Invention of MK-7845, a SARS-CoV-2 3CL Protease Inhibitor Employing a Novel Difluorinated Glutamine Mimic. Journal of Medicinal Chemistry, 67(5), 3935-3958. https://doi.org/10.1021/acs.jmedchem.3c02248

Vancouver

Shurtleff VW, Layton ME, Parish CA, Perkins JJ, Schreier JD, Wang Y, et al. Invention of MK-7845, a SARS-CoV-2 3CL Protease Inhibitor Employing a Novel Difluorinated Glutamine Mimic. Journal of Medicinal Chemistry. 2024;67(5):3935-3958. doi:10.1021/acs.jmedchem.3c02248

BibTeX
@article{Shurtleff2024,
  author = {Shurtleff, Valerie W and Layton, Mark E and Parish, Craig A and Perkins, James J and Schreier, John D and Wang, Yunyi and Adam, Gregory C and Alvarez, Nadine and Bahmanjah, Soheila and Bahnck-Teets, Carolyn M and Boyce, Christopher W and Burlein, Christine and Cabalu, Tamara D and Campbell, Brian T and Carroll, Steven S and Chang, Wonsuk and de Lera Ruiz, Manuel and Dolgov, Enriko and Fay, John F and Fox, Nicholas G and Goh, Shih Lin and Hartingh, Timothy J and Hurzy, Danielle M and Kelly, Michael J and Klein, Daniel J and Klingler, Franca-Maria and Krishnamurthy, Harini and Kudalkar, Shalley and Mayhood, Todd W and McKenna, Philip M and Murray, Edward M and Nahas, Debbie and Nawrat, Christopher C and Park, Steven and Qian, Dongming and Roecker, Anthony J and Sharma, Vijeta and Shipe, William D and Su, Jing and Taggart, Robert V and Truong, Quang and Wu, Yin and Zhou, Xiaoyan and Zhuang, Ningning and Perlin, David S and Olsen, David B and Howe, John A and McCauley, John A},
  title = {Invention of MK-7845, a SARS-CoV-2 3CL Protease Inhibitor Employing a Novel Difluorinated Glutamine Mimic},
  journal = {Journal of Medicinal Chemistry},
  year = {2024},
  volume = {67},
  number = {5},
  pages = {3935--3958},
  doi = {10.1021/acs.jmedchem.3c02248}
}
Kostenlos starten →